SML3352
GSK973
≥98% (HPLC)
别名:
(2S,3S)-N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-2-(fluoromethyl)-N7-methyl-3-phenyl-2,3-dihydrobenzofuran-5,7-dicarboxamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C23H23FN2O4
化学文摘社编号:
分子量:
410.44
UNSPSC Code:
12352200
MDL number:
NACRES:
NA.21
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Orally available, potent and selective pan-second bromodomain (BD2) inhibitor that effectively inhibits LPS-induced MCP-1 release in human whole blood.
GSK973 is an orally available, potent and selective pan-second bromodomain (BD2) inhibitor (BD2/BD1 pIC50 = 7.5/4.4/BRD2, 7.8/4.5/BRD3, 7.8/4.6/BRD4, 7.4/4.5/BRDT) that effectively inhibits LPS-induced MCP-1 release in human whole blood (pIC50 = 7.3; IC50 = 50 nM).
GSK973 is an orally available, potent and selective pan-second bromodomain (BD2) inhibitor (BD2/BD1 pIC50 = 7.5/4.4/BRD2, 7.8/4.5/BRD3, 7.8/4.6/BRD4, 7.4/4.5/BRDT) that effectively inhibits LPS-induced MCP-1 release in human whole blood (pIC50 = 7.3; IC50 = 50 nM).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Alex Preston et al.
ACS medicinal chemistry letters, 11(8), 1581-1587 (2020-08-25)
Pan-BET inhibitors have shown profound efficacy in a number of in vivo preclinical models and have entered the clinic in oncology trials where adverse events have been reported. These inhibitors interact equipotently with the eight bromodomains of the BET family
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML3352-25MG | 04065271199101 |
| SML3352-5MG | 04065271199118 |